UK Companies House feature
AMICUS THERAPEUTICS INTERNATIONAL HOLDING LTD
Profile
- Company number
- 10147996
- Status
- Active
- Incorporation
- 2016-04-26
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 86900
- Hubs
- UK Healthcare
Accounts
Pending extraction
No iXBRL extracted yet for this company.
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“As detailed above Corporate support letters have been issued by Amicus Therapeutics Inc. which itself has been signed off as a going concern, further detail on going concern is contained in section 2.3 of notes to the financial statements below.”
Subsidiaries
- Amicus Therapeutics UK Limited · 100% held · United Kingdom · Commercialisation Ordinary of pharmaceutical products
- Amicus Therapeutics GmbH · 100% held · Germany · Commercialisation Ordinary of pharmaceutical products
- Amicus Therapeutics BV · 100% held · Netherlands · Other human health activities
- Amicus Therapeutics KK · 100% held · Japan · Commercialisation Ordinary of pharmaceutical products
- Amicus Therapeutics SAS · 100% held · France · Commercialisation Ordinary of pharmaceutical products
- Amicus Therapeutics S.r.l · 100% held · Italy · Commercialisation Ordinary of pharmaceutical products
- Amicus Therapeutics SP · 100% held · Spain · Commercialisation Ordinary of pharmaceutical products
- Amicus Therapeutics Canada Inc · 100% held · Canada · Commercialisation Ordinary of pharmaceutical products
- Amicus Therapeutics PTY · 100% held · Australia · Commercialisation Ordinary of pharmaceutical products
- Amicus Therapeutics ApS · 100% held · Denmark · Other human health activities
- Amicus Therapeutics Europe Limited · 100% held · Ireland · Commercialisation Ordinary of pharmaceutical products
- Amicus Therapeutics Switzerland GmbH · 100% held · Switzerland · Commercialisation Ordinary of pharmaceutical products
Significant events
- “The Group is also expanding with new products, in 2023, the European Commission (EC) and UK's Medicines and Healthcare Products Regulatory Agency (MHRA) fully approved Pombiliti + Opfolda for the treatment of late-onset Pompe disease (LOPD).”
- “In October 2023, Amicus Therapeutics Inc. entered into a loan agreement with Blackstone for $400m in order to repay existing group debt and provide adequate working capital for the future. As part of this agreement Amicus Therapeutics International Holding Ltd provided a first lien security interest over cash held in its bank account and its trade debtor balances.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
2 active · 6 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| GREEN, Steven John | Director | 2020-06-01 | Apr 1977 | British |
| STOCKWELL, Caroline Amelia | Director | 2024-04-18 | Nov 1966 | British |
Show 6 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GHYOOT, Geoffrey Marc Caroline | Director | 2016-04-26 | 2017-03-10 |
| MOCHAN, Lori Elizabeth | Director | 2018-05-04 | 2020-02-21 |
| PROUT, Samantha Lynn | Director | 2018-05-04 | 2024-02-01 |
| QUIMI, Daphne Elke | Director | 2021-12-01 | 2024-01-29 |
| QUIMI, Daphne Elke | Director | 2016-04-26 | 2018-05-04 |
| SARKARIA, Jasvinder Singh | Director | 2017-03-21 | 2018-05-04 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Amicus Therapeutics Inc | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-26 | Active |
Filing timeline
Last 20 of 51 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2025-05-07 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2025-04-07 | AA | accounts | accounts with accounts type full |
| 2024-07-08 | PSC05 | persons-with-significant-control | change to a person with significant control |
| 2024-06-11 | PSC05 | persons-with-significant-control | change to a person with significant control |
| 2024-05-18 | AA | accounts | accounts with accounts type full |
| 2024-05-07 | CS01 | confirmation-statement | confirmation statement with updates |
| 2024-04-19 | AP01 | officers | appoint person director company with name date |
| 2024-02-14 | TM01 | officers | termination director company with name termination date |
| 2024-01-30 | TM01 | officers | termination director company with name termination date |
| 2023-12-19 | SH19 | capital | capital statement capital company with date currency figure |
| 2023-12-19 | RESOLUTIONS | resolution | resolution |
| 2023-12-19 | CAP-SS | insolvency | legacy |
| 2023-12-19 | SH20 | capital | legacy |
| 2023-10-23 | RESOLUTIONS | resolution | resolution |
| 2023-10-23 | MA | incorporation | memorandum articles |
| 2023-10-13 | AA | accounts | accounts with accounts type full |
| 2023-10-12 | SH01 | capital | capital allotment shares |
| 2023-10-12 | MR04 | mortgage | mortgage satisfy charge full |
| 2023-10-09 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2023-05-04 | RP04CS01 | confirmation-statement | second filing of confirmation statement with made up date |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Credit score requires extracted accounts data.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory
Activity Score not yet computed for this company.